Replimune Group, Inc. (NASDAQ:REPL) Given Average Rating of “Buy” by Analysts

Replimune Group, Inc. (NASDAQ:REPL) has been assigned a consensus recommendation of “Buy” from the six analysts that are presently covering the company, Marketbeat reports. Five analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $16.80.

A number of equities analysts have recently commented on REPL shares. JPMorgan Chase & Co. boosted their price target on Replimune Group from $14.00 to $17.00 and gave the stock an “overweight” rating in a report on Tuesday, September 24th. Roth Mkm assumed coverage on shares of Replimune Group in a report on Tuesday, August 27th. They issued a “buy” rating and a $17.00 price objective for the company. HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Replimune Group in a report on Monday, September 16th. Finally, Roth Capital raised shares of Replimune Group to a “strong-buy” rating in a research note on Tuesday, August 27th.

Insiders Place Their Bets

In other Replimune Group news, CFO Emily Luisa Hill sold 8,938 shares of the stock in a transaction dated Friday, August 16th. The stock was sold at an average price of $10.18, for a total transaction of $90,988.84. Following the completion of the sale, the chief financial officer now directly owns 101,057 shares in the company, valued at approximately $1,028,760.26. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 8.80% of the company’s stock.

Institutional Trading of Replimune Group

Several large investors have recently modified their holdings of REPL. Millennium Management LLC grew its holdings in Replimune Group by 575.1% in the second quarter. Millennium Management LLC now owns 3,118,035 shares of the company’s stock worth $28,062,000 after purchasing an additional 2,656,173 shares during the period. Price T Rowe Associates Inc. MD increased its position in Replimune Group by 12.0% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 6,548,930 shares of the company’s stock valued at $53,505,000 after buying an additional 699,679 shares in the last quarter. Jacobs Levy Equity Management Inc. bought a new position in Replimune Group in the first quarter worth approximately $1,088,000. Acadian Asset Management LLC acquired a new stake in Replimune Group in the first quarter valued at approximately $927,000. Finally, Cubist Systematic Strategies LLC increased its holdings in shares of Replimune Group by 282.2% during the second quarter. Cubist Systematic Strategies LLC now owns 72,207 shares of the company’s stock valued at $650,000 after acquiring an additional 53,313 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company’s stock.

Replimune Group Stock Performance

Shares of Replimune Group stock opened at $12.50 on Tuesday. The company has a 50 day moving average of $11.33 and a 200-day moving average of $9.40. The company has a market cap of $854 million, a PE ratio of -3.82 and a beta of 1.19. The company has a current ratio of 13.46, a quick ratio of 13.46 and a debt-to-equity ratio of 0.16. Replimune Group has a 1-year low of $4.92 and a 1-year high of $12.97.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.